SNAP heads into its Q4 earnings report with ad momentum, growing subscriptions and regulatory headwinds shaping expectations for the stock.

RIVN's upcoming R2 SUV, aggressive cost cuts and a multibillion-dollar Volkswagen partnership give it an edge over NIO in the EV stock debate.

On Wednesday, Amphenol sank on fears its data center sales might slow. Investors could have the same concerns for Celestica ahead of its earnings.

abrdn Healthcare Investors (HQH) offers exposure to a recovering healthcare sector, yet trades at an ~8% discount to NAV. HQH's portfolio emphasizes late-stage and commercial-stage healthcare companies, benefiting from reduced Medicare policy uncertainty and sector stabilization. The fund's high yield (~12%) is fully supported by realized gains, not return of capital or net investment income.

Amazon said Tuesday (Jan. 28) that it is cutting roughly 16,000 jobs across its global workforce, marking one of the largest headcount reductions in the company's history.

General Dynamics beats Q4 earnings and revenue estimates, with Marine Systems and Combat Systems driving solid year-over-year growth.

New luxury community features carriage-style townhomes and onsite amenities, specifically designed for active-adults New luxury community features carriage-style townhomes and onsite amenities, specifically designed for active-adults

ASML Holding N.V. (ASML) Q4 2025 Press Conference Call Transcript

Navient Corporation (NAVI) Q4 2025 Earnings Call Transcript

Littelfuse, Inc. (LFUS) Q4 2025 Earnings Call Transcript

PGR's fourth-quarter 2025 results reflect a year-over-year improvement in premiums.

The headline numbers for Stellar Bancorp (STEL) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The headline numbers for Progressive (PGR) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Although the revenue and EPS for Brinker International (EAT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Historically, NVDA has undergone several significant rallies. The stock jumped over 50% within two months on 11 separate occasions, particularly in 2016 and 2024, and increased by more than 30% in similar timeframes 15 times, including pivotal years like 2017 and 2024.

Palantir Technologies Inc. remains a Buy, but valuation is demanding and upside is now more normalized based on a fundamentally driven EV/EBITDA approach. PLTR's elite growth hinges on maintaining the "Rule of 80"—combined revenue growth and margins—supporting a base case price target of $183.84 (11% upside). Risks include premium valuation tied to AI optimism and potential international/commercial growth headwinds due to geopolitical tensions and CEO's pro-US stance.

Progressive is upgraded to "Buy" as shares reach my $210 target, trading at ~12x earnings with a de-risked valuation. PGR's Q4 results beat estimates, with a strong 87.1% combined ratio and disciplined underwriting despite industry margin concerns. Premium growth is slowing as PGR prioritizes margins over volume, but policy count remains robust, up 10% year over year.

Texas Instruments Inc (NASDAQ:TXN) shares are up 8.2% to trade at $212.80 at last glance, brushing off disappointing fourth-quarter results of $1.27 per share and revenue of $4.42 billion.

NFLX's Q4 beat shows revenue, margin and subscriber gains, plus bold 2026 guidance, yet recent stock weakness and valuation argue for patience.

Eli Lilly and Co (NYSE:LLY) announced that it has entered a strategic global research collaboration and licensing agreement with Seamless Therapeutics to develop and commercialize programmable recombinase-based treatments for certain hearing loss indications. The collaboration will use Seamless' proprietary recombinase platform, which enables large, precise DNA insertions independent of the cell's natural DNA repair mechanisms.